Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
2007

Comparing Epoetin Delta Dosing in Kidney Disease

Sample size: 416 publication Evidence: moderate

Author Information

Author(s): Iain C Macdougall

Primary Institution: King's College Hospital

Hypothesis

Is once weekly dosing of epoetin delta non-inferior to twice weekly and once every two weeks dosing in patients with chronic kidney disease?

Conclusion

The trial aims to determine the best dosing frequency for epoetin delta in managing anaemia in chronic kidney disease patients.

Supporting Evidence

  • Anaemia is a common complication of chronic kidney disease.
  • Epoetin delta is effective in maintaining haemoglobin levels in anaemic patients.
  • The trial will help guide appropriate dosing frequency for epoetin delta.

Takeaway

This study is trying to find out how often patients with kidney disease should take a medicine called epoetin delta to help with their anaemia.

Methodology

This is a randomized, open-label, multicentre trial involving patients aged 18 and above with chronic kidney disease, comparing different dosing regimens of epoetin delta.

Potential Biases

Potential bias in patient selection and reporting of outcomes.

Limitations

The study may not account for all variables affecting anaemia management in chronic kidney disease.

Participant Demographics

Patients aged 18 years or older with chronic kidney disease (Stages 3–5).

Statistical Information

Confidence Interval

95% CI for the difference between dosing regimens.

Digital Object Identifier (DOI)

10.1186/1745-6215-8-35

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication